58610-70-1

Basic information

• Product Name: 1-benzyl-2-(chloromethyl)-1H-imidazole(SALTDATA: HCl)
• Synonyms: 1-benzyl-2-(chloromethyl)-1H-imidazole(SALTDATA: HCl);1-benzyl-2-chloromethylimidazole
• CAS NO: 58610-70-1
• Molecular Formula: C₁₁H₁₁ClN₂
• Molecular Weight: 206.67144
• Mol File: 58610-70-1.mol
• Article Data: 4

Chemical Properties

• Melting Point: 181-182 °C
• Boiling Point: 333.4±25.0 °C(Predicted)
• Appearance: /
• Density: 1.16±0.1 g/cm3(Predicted)
• PKA: 6.00±0.31(Predicted)
• CAS DataBase Reference: 1-benzyl-2-(chloromethyl)-1H-imidazole(SALTDATA: HCl)(CAS DataBase Reference)
• NIST Chemistry Reference: 1-benzyl-2-(chloromethyl)-1H-imidazole(SALTDATA: HCl)(58610-70-1)
• EPA Substance Registry System: 1-benzyl-2-(chloromethyl)-1H-imidazole(SALTDATA: HCl)(58610-70-1)

Safety Data

• Hazardous Substances Data: 58610-70-1(Hazardous Substances Data)

Usage

Definition

ChEBI: An imidazole derivative containing benzyl and chloromethyl substituents at positions 1 and 2, respectively.

Upstream product

• 5376-10-3 1-benzyl-2-(hydroxymethyl)imidazole 
• 4238-71-5 1-benzylimidazole 
• 19276-03-0 1-(phenylmethyl)-2-chloromethyl-1H-imidazole monohydrochloride 
• 5272-57-1 1-benzyl-2-(hydroxymethyl)imidazole hydrochloride 

Downstream Products

• 19276-04-1 3-benzyl-2-methyl-3H-imidazole-4-carbonitrile 
• 102152-07-8 (S)-5-<<4-<<2-(1-benzyl)imidazolyl>methoxy>phenoxy>methyl>-3-<2-(3,4-dimethoxyphenyl)ethyl>oxazolid-2-one 
• 1026629-22-0 N-[1-(1-benzyl-1H-imidazol-2-ylmethyl)-2-oxo-butyl]-propionamide 
• 945543-30-6 4-(1-benzyl-1H-imidazol-2-ylmethyl)-heptane-3,5-dione 
• 1086280-95-6 1'-[(1-benzyl-1H-imidazol-2-yl)methyl]-1-quinolin-3-ylspiro[indole-3,4'-piperidin]-2(1H)-one 
• 380200-33-9 3-(1-Benzyl-1H-imidazol-2-ylmethyl)-8-(3,5-bis-trifluoromethyl-benzoyl)-1-(2-chloro-phenyl)-1,3,8-triaza-spiro[4.5]decan-4-one 
• 19276-07-4 C-(3-benzyl-2-methyl-3H-imidazol-4-yl)-methylamine 

Relevant articles and documents

Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives

The present invention relates a method for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, R1, R2, A and n are as defined in the specification and to their pharmaceutically active salts. The invention also relates to novel compounds of formula I, pharmaceutical compositions containing them, and methods for their preparation.

SYNTHESIS OF CYANO OXIMES BASED ON AZOLES AND AZINES AND THE EFFECT OF THEIR PROTON-ACCEPTING CHRACTERISTICS ON THE STABILITY OF THE COMPLEXES OF THE LIGANDS WITH THE Fe(II) ION

In the series of ligand systems based on ?-deficient azoles and azines with a hydroxyiminocyanomethyl complexing group at the α position to the pyridine-type nitrogen atom the basicity of the heterocyclic nitrogen atom decreases during benzannelation.A comparative assesment was made of the complexing capacity of cyano oximes and the stability of their chelate compounds with the Fe(II) ion.